News
CBAY
--
0.00%
--
KPTI, CENX, GMAB and TCRR among after-hours movers
Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%.
Seekingalpha · 2d ago
Free Fatty Acid Receptor 4 Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Market Insight Reports · 4d ago
BRIEF-CymaBay Appoints Thomas Wiggans And Janet Dorling To Board
reuters.com · 6d ago
Press Release: CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
Dow Jones · 6d ago
Global Free Fatty Acid Receptor 4 Market Size, Share, Value, and Competitive Landscape 2020
Apr 05, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 6d ago
Global Primary Biliary Cirrhosis Drug Market 2021-2027 with Top Countries Data Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast | With Covid-19 Analysis
The Express Wire · 6d ago
--Analyst Actions: Cantor Fitzgerald Adjusts Cymabay Therapeutics' Price Target to $7 From $20, Maintains Overweight Rating
MT Newswires · 03/31 09:43
Oppenheimer Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)
Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY) today and set a price target of $14.00. The company's shares closed
SmarterAnalyst · 03/26 19:25
B.Riley Financial Reiterates Their Buy Rating on CymaBay Therapeutics (CBAY)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on CymaBay Therapeutics (CBAY), with a price target of $13.00.
SmarterAnalyst · 03/26 17:35
CymaBay Therapeutics (CBAY) Received its Third Buy in a Row
After Piper Sandler and Oppenheimer gave CymaBay Therapeutics (NASDAQ: CBAY) a Buy rating last month, the company received another Buy, this time from
SmarterAnalyst · 03/26 13:25
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY), ADMA Biologics (ADMA) and Brainsway (BWAY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CymaBay Therapeutics (CBAY), ADMA Biologics (ADMA) and
SmarterAnalyst · 03/26 11:25
DJ Cymabay Therapeutics, Inc. CEO Sujal Shah on Q4 2020 Results -- Earnings Call Transcript >CBAY
Dow Jones · 03/26 05:47
Newer approaches for the management of Cholestatic Pruritus treatment outlook
Newer approaches for the management of Cholestatic Pruritus treatment outlook
GlobeNewswire · 03/26 00:20
CymaBay Therapeutics Q4 EPS $(0.23) Misses $(0.20) Estimate
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.20) by 15 percent. This is a 46.51 percent increase over losses of $(0.43) per share
Benzinga · 03/25 20:18
CymaBay Therapeutics 4Q Loss $15.8M >CBAY
CymaBay Therapeutics 4Q Loss $15.8M >CBAY
Dow Jones · 03/25 20:15
CymaBay Therapeutics 4Q Loss/Shr 23c >CBAY
CymaBay Therapeutics 4Q Loss/Shr 23c >CBAY
Dow Jones · 03/25 20:15
CymaBay Therapeutics EPS misses by $0.03
CymaBay Therapeutics (CBAY): Q4 GAAP EPS of -$0.23 misses by $0.03.Held $146.3 million in cash, cash equivalents and short-term investments on December 31, 2020. We believe that cash and investments
Seekingalpha · 03/25 20:13
Press Release: CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
Dow Jones · 03/25 20:10
CymaBay Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 25, 2021 / CymaBay Therapeutics, Inc. (NASDAQ:CBAY) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 25, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 03/25 18:31
Cymabay Therapeutics Q4 Loss Shrinks; Shares Down After Hours
MT Newswires · 03/25 16:43
Webull provides a variety of real-time CBAY stock news. You can receive the latest news about CymaBay through multiple platforms. This information may help you make smarter investment decisions.
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.